• 1
    Autran B, Carcelain G, Li TS et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997; 277:11216.
  • 2
    Lederman HM, Williams PL, Wu JW et al. Incomplete immune reconstitution after initiation of highly active antiretroviral therapy in human immunodeficiency virus-infected patients with severe CD4+ cell depletion. J Infect Dis 2003; 188:1794803.
  • 3
    Connors M, Kovacs JA, Krevat S et al. HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat Med 1997; 3:53340.
  • 4
    Guadalupe M, Reay E, Sankaran S et al. Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J Virol 2003; 77:1170817.
  • 5
    De Maria A. Discordant responses to HAART in HIV-1 patients: the need to focus on intervention. Exp Rev Anti Infect Ther 2007; 5:5237.
  • 6
    Moore DM, Hogg RS, Yip B et al. Discordant immunologic and virologic responses to highly active antiretroviral therapy are associated with increased mortality and poor adherence to therapy. J Acquir Immune Defic Syndr 2005; 40:28893.
  • 7
    Anthony KB, Yoder C, Metcalf JA et al. Incomplete CD4 T cell recovery in HIV-1 infection after 12 months of highly active antiretroviral therapy is associated with ongoing increased CD4 T cell activation and turnover. J Acquir Immune Defic Syndr 2003; 33:12533.
  • 8
    Fleury S, Rizzardi GP, Chapuis A et al. Long-term kinetics of T cell production in HIV-infected subjects treated with highly active antiretroviral therapy. Proc Natl Acad Sci USA 2000; 97:53938.
  • 9
    Carbonneil C, Donkova-Petrini V, Aouba A, Weiss L. Defective dendritic cell function in HIV-infected patients receiving effective highly active antiretroviral therapy: neutralization of IL-10 production and depletion of CD4+CD25+ T cells restore high levels of HIV-specific CD4+ T cell responses induced by dendritic cells generated in the presence of IFN-{alpha}. J Immunol 2004; 172:783240.
  • 10
    Almeida M, Cordero M, Almeida J, Orfao A. Persistent abnormalities in peripheral blood dendritic cells and monocytes from HIV-1-positive patients after 1 year of antiretroviral therapy. J Acquir Immune Defic Syndr 2006; 41:40515.
  • 11
    Gazzard B, Bernard AJ, Boffito M et al. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Med 2006; 7:487503.
  • 12
    Hammer S, Eron JJ, Reiss P et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society–USA panel. JAMA 2008; 300:55570.
  • 13
    Dickinson L, Boffito M, Khoo SH et al. Pharmacokinetic analysis to assess forgiveness of boosted saquinavir regimens for missed or late dosing. J Antimicrob Chemother 2008; 62:1617.
  • 14
    Shuter J. Forgiveness of non-adherence to HIV-1 antiretroviral therapy. J Antimicrob Chemother 2008; 61:76973.
  • 15
    Kearney BP, Sayre JR, Flaherty JF, Chen SS, Kaul S, Cheng AK. Drug–drug and drug–food interactions between tenofovir disoproxil fumarate and didanosine. J Clin Pharmacol 2005; 45:13607.
  • 16
    Ray AS, Olson L, Fridland A. Role of purine nucleoside phosphorylase in interactions between 2′,3′-dideoxyinosine and allopurinol, ganciclovir, or tenofovir. Antimicrob Agents Chemother 2004; 48:108995.
  • 17
    Barrios A, Rendon A, Negredo E et al. Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine. AIDS 2005; 19:56975.
  • 18
    Negredo E, Molto J, Burger D et al. Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load. AIDS 2004; 18:45963.
  • 19
    Torti C, Lapadula G, Barreiro P et al. CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load. J Antimicrob Chemother 2007; 59:11417.
  • 20
    Di Biagio A, Beltrame A, Cenderello G, Ferrea G, De Maria A. Clinically stable treatment-experienced adults receiving tenofovir and didanosine. HIV Clin Trials 2006; 7:1015.
  • 21
    Karrer U, Ledergerber B, Furrer H et al. Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir. AIDS 2005; 19:198794.
  • 22
    Henry WK, Tebas P, Lane HC. Explaining, predicting, and treating HIV-associated CD4 cell loss: after 25 years still a puzzle. JAMA 2006; 296:15235.
  • 23
    Barreiro P, Soriano V. Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir. J Antimicrob Chemother 2006; 57:8069.
  • 24
    Aquaro S, Svicher V, Schols D et al. Mechanisms underlying activity of antiretroviral drugs in HIV-1-infected macrophages: new therapeutic strategies. J Leukoc Biol 2006; 80:110310.
  • 25
    Delmonte OM, Bertolotto G, Ricotti E, Tovo P-A. Immunomodulatory effects of two HIV protease inhibitors, Saquinavir and Ritonavir, on lymphocytes from healthy seronegative individuals. Immunol Lett 2007; 111:11115.
  • 26
    D'Ettorre G, Forcina G, Andreotti M et al. Interleukin-15 production by monocyte-derived dendritic cells and T cell proliferation in HIV-infected patients with discordant response to highly active antiretroviral therapy. Clin Exp Immunol 2004; 135:2805.
  • 27
    Krathwohl MD, Schacker TW, Anderson JL. Abnormal presence of semimature dendritic cells that induce regulatory T cells in HIV-infected subjects. J Infect Dis 2006; 193:494504.
  • 28
    Fogli M, Costa P, Murdaca G et al. Significant NK cell activation associated with decreased cytolytic function in peripheral blood of HIV-1-infected patients. Eur J Immunol 2004; 34:231321.
  • 29
    De Maria A, Fogli M, Costa P et al. The impaired NK cell cytolytic function in viremic HIV-1 infection is associated with a reduced surface expression of natural cytotoxicity receptors (NKp46, NKp30 and NKp44). Eur J Immunol 2003; 33:241018.
  • 30
    Azzoni L, Papasavvas E, Chehimi J et al. Sustained impairment of IFN-gamma secretion in suppressed HIV-infected patients despite mature NK cell recovery: evidence for a defective reconstitution of innate immunity. J Immunol 2002; 168:576470.
  • 31
    Goodier MR, Mela CM, Steel A, Gazzard B, Bower M, Gotch F. NKG2C+ NK cells are enriched in AIDS patients with advanced-stage Kaposi's sarcoma. J Virol 2007; 81:4303.
  • 32
    Moretta A, Marcenaro E, Parolini S, Ferlazzo G, Moretta L. NK cells at the interface between innate and adaptive immunity. Cell Death Differ 2007; 5:22633.
  • 33
    Azzoni L, Rutstein RM, Chehimi J, Farabaugh MA, Nowmos A, Montaner LJ. Dendritic and natural killer cell subsets associated with stable or declining CD4+ cell counts in treated HIV-1-infected children. J Infect Dis 2005; 191:14519.
  • 34
    Mavilio D, Lombardo G, Kinter A et al. Characterization of the defective interaction between a subset of natural killer cells and dendritic cells in HIV-1 infection. J Exp Med 2006; 203:233950.
  • 35
    Costa P, Rusconi S, Fogli M et al. Low expression of inhibitory natural killer receptors in CD8 cytotoxic T lymphocytes in long-term non-progressor HIV-1-infected patients. AIDS 2003; 17:25760.
  • 36
    Costa P, Rusconi S, Mavilio D et al. Differential disappearance of inhibitory natural killer cell receptors during HAART and possible impairment of HIV-1-specific CD8 cytotoxic T lymphocytes. AIDS 2001; 15:96574.
  • 37
    Mavilio D, Lombardo G, Benjamin J et al. Characterization of CD56-/CD16+ natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals. Proc Natl Acad Sci USA 2005; 102:288691.
  • 38
    Bongiovanni M, Gianotti N, Chiesa E et al. Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone. Infection 2007; 35:4516.
  • 39
    Clotet B, Negredo E, Girard PM, Youle M, Neubacher D. Compromised immunologic recovery in patients receiving tipranavir/ritonavir coadministered with tenofovir and didanosine in Randomized Evaluation of Strategic Intervention in multidrug-resiStant patients with Tipranavir (RESIST) studies. J Acquir Immune Defic Syndr 2007; 45:47981.
  • 40
    Vitale M, Della Chiesa M, Carlomagno S et al. NK-dependent DC maturation is mediated by TNFalpha and IFNgamma released upon engagement of the NKp30 triggering receptor. Blood 2005; 106:56671.
  • 41
    Ferlazzo G, Morandi B, D'Agostino A et al. The interaction between NK cells and dendritic cells in bacterial infections results in rapid induction of NK cell activation and in the lysis of uninfected dendritic cells. Eur J Immunol 2003; 33:30613.
  • 42
    Ferlazzo G, Tsang ML, Moretta L, Melioli G, Steinman RM, Munz C. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med 2002; 195:34351.